Linke B, Bolz I, Pott C, Hiddemann W, Kneba M
Department of Internal Medicine, Georg-August University, Goettingen, Germany.
Leukemia. 1995 Dec;9(12):2133-7.
The development of rapid PCR protocols for amplification of rearranged IgH gene sequences has greatly facilitated the identification of clonal IGH rearrangements in non-Hodgkin's lymphomas (NHL) and leukemias. However, the 15-35% incidence of false negative results with this approach has been a constant and unresolved problem. To assess the reliability of a previously published framework region 3 (FR3A) IgH-CDR3-PCR for detection of monoclonal IgH gene rearrangements we compared the PCR and Southern results in a series of 44 NHL and leukemias of B cell lineage showing a JH-rearrangement in Southern analysis with genomic DNA and hybridization with a IgH joining region (JH) probe. IgH-CDR3 regions were amplified using DNA extracted from clinical specimens by PCR using fluorescent dye-labeled consensus primers homologous to conserved regions within the variable (VH) and the joining (JH) gene segments. The PCR products were size separated on a high resolution polyacrylamide gel and analyzed for clonality by exact size determination and fluorescence quantification in an automated DNA sequencer. With commonly used DNA polymerases monoclonal IgH-CDR3 junctions were identified in 36/44 samples (82%). However, in the remaining eight cases (18%) with pathohistologically clearly demonstrated B cell malignancies which were also monoclonal on JH-Southern analysis, monoclonality could be demonstrated by FR3A-IgH-CDR3-PCR only with the proofreading UITma DNA polymerase. In four of these monoclonal VH--N--DH--N--JH junctions sequence analysis was performed which showed a point mutation in one and a single nucleotide deletion at the 3' terminus of the primer target site in the other case. In the remaining two cases no primer mismatches could be identified. Thus we conclude that the marked improvement of the PCR-detection rate of monoclonal IgH-CDR3 junctions was achieved at least in part due to the ability of UITma DNA polymerase to remove mismatched bases at the 3' terminus of the primers with respect to the target during the first amplification cycles. Our results suggest, that UITma is the DNA polymerase of choice for amplification of IgH-CDR3 junctions with consensus FR3A-VH- and JH-primers.
用于扩增重排IgH基因序列的快速PCR方案的发展极大地促进了非霍奇金淋巴瘤(NHL)和白血病中克隆性IGH重排的鉴定。然而,这种方法有15 - 35%的假阴性结果发生率,一直是个持续存在且未解决的问题。为了评估先前发表的框架区3(FR3A)IgH - CDR3 - PCR检测单克隆IgH基因重排的可靠性,我们比较了44例B细胞系NHL和白血病的PCR和Southern结果,这些病例在Southern分析中显示与基因组DNA有JH重排,并与IgH连接区(JH)探针杂交。使用从临床标本中提取的DNA,通过PCR扩增IgH - CDR3区域,所用荧光染料标记的共有引物与可变区(VH)和连接区(JH)基因片段内的保守区域同源。PCR产物在高分辨率聚丙烯酰胺凝胶上进行大小分离,并在自动DNA测序仪中通过精确的大小测定和荧光定量分析其克隆性。使用常用的DNA聚合酶,在36/44个样本(82%)中鉴定出单克隆IgH - CDR3连接。然而,在其余8例(18%)病例中,病理组织学明确显示为B细胞恶性肿瘤,且在JH - Southern分析中也是单克隆的,只有使用校对的UITma DNA聚合酶,FR3A - IgH - CDR3 - PCR才能证明其单克隆性。对其中4个单克隆VH - N - DH - N - JH连接进行了序列分析,其中1个显示有一个点突变,另1个在引物靶位点的3'末端有一个单核苷酸缺失。在其余2例中未发现引物错配。因此我们得出结论,单克隆IgH - CDR3连接的PCR检测率的显著提高至少部分归因于UITma DNA聚合酶在第一个扩增循环中能够去除引物3'末端相对于靶标的错配碱基。我们的结果表明,UITma是使用共有FR3A - VH和JH引物扩增IgH - CDR3连接的首选DNA聚合酶。